海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- 104 Week Trial to Evaluate the Comparative Effectiveness of dapagliflozin and Standard of Care in Type 2 Diabetes. The DECIDE Study.
- Type 2 diabetes mellitus MedDRA version: 20.0 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- United Kingdom
- 2015-09-01
Authorised
- Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resection
- Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases) MedDRA version: 20.0 Level: PT Classification code 10025670 Term: Malignant melanoma stage III System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Poland, Portugal, Russian Federation, Serbia, Singapore, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States
- 2015-04-21
Authorised
- Efficacy of eltrombopag plus lenalidomide combination therapy in patients with IPSS low and intermediate-risk myelodysplastic syndrome with isolated del5q: a multicenter, randomized, double-blind, placebo controlled study
- Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with isolated del(5q) MedDRA version: 19.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851 MedDRA version: 19.0 Level: LLT Classification code 10067096 Term: 5q minus myelodysplastic syndrome System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- France
- 2016-11-30
Authorised
- pre-operative nivolumab, ipilimumab and COC2-inhibition in olon cancer (NICHE)
- stage 1-3 adenocarcinoma of the colon MedDRA version: 19.0 Level: LLT Classification code 10009957 Term: Colon carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2016-09-19
Authorised
- Usefulness of the measurement of blood levels of infliximab and adalimumab in inflammatory bowel disease patients in predicting response to treatment
- Inflammatory bowel disease MedDRA version: 14.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 14.1 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- United Kingdom
- 2012-08-15
Authorised
- Effects of liraglutide on pancreatic function in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
- Type 2 Diabetes mellitus MedDRA version: 14.1 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Italy
- 2012-06-20
Authorised
- A randomized phase II study of FOLFORI plus or not CETUXIMAB in elderly advanced colorectal cancer patients.
- Elderly mestatic colorectal cancer patients, Wild-type KRAS ,70-80 years of age, ECOG 0-1. MedDRA version: 14.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2012-04-02
Authorised
- Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Together and/or Separately According to Different Schedules to Healthy Subjects
- Safety and Immunogenicity of Rabies Vaccine and Japanese Encephalitis Vaccine administered concomitantly and/or separately according to 1 of 2 different pre-exposure prophylaxis schedules to healthy adult subjects MedDRA version: 14.1 Level: PT Classification code 10037742 Term: Rabies System Organ Class: 10021881 - Infections and infestations MedDRA version: 14.1 Level: LLT Classification code 10023123 Term: Japanese encephalitis System Organ Class: 10021881 - Infections and infestations MedDRA version: 14.1 Level: HLT Classification code 10037743 Term: Rabies viral infections System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Austria, Germany, Switzerland
- 2012-01-25
Authorised
- ENSAYO CLÍNICO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE INTERFERÓN PEGILADO MÁS RIBAVIRINA MÁS NITAZOXANIDA EN INDIVIDUOS CON HEPATITIS CRÓNICA DEBIDA A GENOTIPO 4 DEL VHC Y COINFECTADOS POR VIH
- Infección por el VIH-1 y el genotipo 4 del virus de la hepatitis C MedDRA version: 14.0 Level: LLT Classification code 10065949 Term: HCV coinfection System Organ Class: 10021881 - Infections and infestations MedDRA version: 14.0 Level: LLT Classification code 10008922 Term: Chronic infection with HIV System Organ Class: 10021881 - Infections and infestations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Spain
- 2010-12-20
Authorised
- A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)
- Histologically/cytologically confirmed diagnosis of metastatic NSCLC. Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion. Performance status of 0-1 according to ECOG score. ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2013-08-19
Authorised
- A study to test a potential new treatment for COPD patients suffering from the common cold or influenza.
- Patients with Chronic Obstructive Pulmonary Disease (COPD). In part 1 of the study the patients are in stable state. In part 2 of the study patients have a respiratory virus infection (i.e. cold or flu virus). MedDRA version: 20.0 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000015472 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- United Kingdom
- 2017-10-06
Authorised
- Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLC
- Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC) MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2017-09-14
Authorised
- A study to investigate how the body responds to the study drug Vedolizumab in child patients with Ulcerative Colitis or Crohn’s Disease
- Ulcerative Colitis and Crohn’s Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Belgium, Canada, France, Germany, Hungary, Israel, Netherlands, Poland, Ukraine, United Kingdom, United States
- 2017-09-14
Authorised
- Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLC
- Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC) MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2017-09-05
Authorised
- Phase 3 1L Study of Pembrolizumab ± Ipilimumab in NSCLC
- Metastatic programmed cell deathligand 1 (PD-L1) positive (TPS =50%) non-small cell lung cancer (NSCLC) MedDRA version: 20.0 Level: PT Classification code 10029522 Term: Non-small cell lung cancer stage IV System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Hungary, Ireland, Italy, Korea, Republic of, Latvia, Mexico, New Zealand, Peru, Poland, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2017-09-01
Authorised
- A randomized, prospective trial of 2-6 weeks pre-operative hormonal treatment for hormone receptor positive breast cancer: Anastrozole +/- Fulvestrant or Tamoxifen Exposure - response in molecular profile (AFTER study) - AFTER study
- Invasive Breast Cancer, tumor size >= 1 cm (NOT inflammatory breast cancer), no clues of metastatic disease, no multicentric breast cancer
- Netherlands
- 2008-03-06
Authorised
- Long-term study on the safety and efficacy of Omnitrope® (rhGH) in short children born Small for Gestational Age
- Growth disturbance (current height standard deviation score (SDS) 1) in short children born small for gestational age (SGA), with a birth weight and/or length below -2 standard deviation (SD), who failed to show catch-up growth (height velocity (HV) SDS MedDRA version: 14.1 Level: LLT Classification code 10018747 Term: Growth hormone System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Belgium, Czech Republic, Germany, Hungary
- 2007-06-21
Authorised
- randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy - FIAVS
- Allergic diseases such as rhinoconjunctivitis or bronchial asthma are a major public health burden. The huge associated costs demand an evidence based therapeutic aproach. The only available causative therapy is the specific immuno-therapy (SIT). Auto-vaccine is another biogen substance, which derives from human-GI-tract bacteria. Its subcutaneous administration results in a Th-1 driven shift towards immunotolerance.
- Germany
- 2005-11-23
Authorised
- Estudio en fase 2 de LY2605541 comparado con insulina Glargina para el tratamiento de pacientes con Diabetes Mellitus tipo 2. A Phase 2 Study of LY2605541 Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus
- Diabetes Mellitus tipo 2 MedDRA version: 9 Level: LLT Classification code 10053247 Term: Insulin-requiring type 2 diabetes mellitus
- Hungary, Spain
- 2009-11-26
Authorised
- The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2
- Diabetes mellitus type 2 MedDRA version: 9.1 Level: LLT Classification code 10012613 Term: Diabetes mellitus non-insulin-dependent MedDRA version: 9.1 Level: LLT Classification code 10012619 Term: Diabetes mellitus poor control MedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus MedDRA version: 9.1 Level: LLT Classification code 10063624 Term: Type II diabetes mellitus inadequate control
- Germany
- 2009-09-23
